$TGL one to watch Monday ππ₯
52-week range $2.04 - $58.00
That $58 high is real β $TGL exploded after its Dec. 2025 reverse split with massive momentum/volume before eventually getting crushed back down.
Now around $2.50, sitting just off 52-week lows.
π₯ Shares recently became accessible through Binance Stocks Trading, potentially expanding global exposure.
π° Agreements to sell its V Gallant + Reveillon interests for $6.6M, bringing additional liquidity over 36 months.
π» Recently signed $3M in software development agreements tied to its Lifestyle Membership & Experience Platform.
After the brutal selloff, $TGL has already bounced roughly 24% off the $2.04 low.
Former $58 momentum runner + near 52-week lows + fresh developments.
If volume comes back, this one could get interesting FAST.
$TGL on watch Monday ππ₯
3
5
1,711
$VTGN π
πΉοΈ Yesterday's multibillion-dollar Eli Lilly acquisition of AtaiBeckley $ATAI shows Big Pharma is willing to pay a premium for innovative intranasal CNS therapies.
πΉοΈ Vistagen's pipeline is also built around a proprietary intranasal pherine platform targeting brain neurocircuitry with rapid-onset, non-systemic treatments.
πΉοΈ Refisolone (PH80) is being developed as a non-hormonal treatment for menopausal hot flashes, a massive unmet market, and the company is also in discussions with Fuji Pharma regarding Japan.
πΉοΈ Different science and different indications than Lilly's acquisitionβbut today's deal highlights continued pharmaceutical interest in novel intranasal CNS technologies.
πΉοΈ If VTGN delivers positive clinical and partnership progress, it could become a company that larger pharmaceutical firms watch closely.
π One to keep on the radar.
#VTGN #Biotech #Stocks #SmallCaps
Not financial advice. For informational purposes only.
2
6
2,496
π $FRGT gaining momentum again, up 11% premarket. The story is starting to get noticed.
πΉ Tiny tradable float can amplify moves when volume pours in.
πΉ AI-powered cross-border logistics and freight tech remain the core growth narrative.
πΉ If momentum continues and more traders discover the setup, I still believe $20+ is achievable over time.
π I'm holding and letting the thesis play out. Patience is often rewarded when the market finally catches on.
Not financial advice. Do your own due diligence.
$ROLR ππ₯ Trading just under $7 and looking like it wants another leg higher.
πΉοΈ The prediction markets story is gaining traction with regulatory approvals and the U.S. rollout continuing to advance.
πΉοΈ Recent addition to the Russell Microcap Index increases visibility and could help attract additional institutional interest.
πΉοΈ If buyers keep stepping in and volume expands, a break above the recent resistance could trigger another momentum move.
πΉοΈ Tight share structure and a hot sector make this one worth watching closely. Momentum names can move fast once key levels break.
πΉοΈ Watching for a clean breakout above $7. If that happens, I think traders will start targeting higher prices in a hurry.
π On watch. Could be just getting started.
**Not financial advice. Do your own DD.**
$FRGT ππ₯ Next $SDOT? Don't miss this one.
πΉοΈ AI transformation is accelerating as management shifts away from traditional freight brokerage toward a software-first, AI-powered logistics company.
πΉοΈ Cost-cutting and restructuring are designed to improve margins and position the business for long-term scalable growth.
πΉοΈ The market is still pricing FRGT like an old-school freight broker while the company continues executing its AI logistics strategy.
πΉοΈ Low float + growing AI narrative + improving business model = a combination that can attract momentum traders in a hurry.
πΉοΈ If this story continues to gain attention, I believe FRGT has the potential to become the next $SDOT-type runner.
π On my watchlist and still accumulating.
**Not financial advice. Do your own DD.**
$FRGT π
This one is getting my attention again.
π Tiny tradable float of roughly 560K shares after multiple reverse splits makes it highly reactive to volume.
π Shares outstanding are approximately 5.5M, with very little institutional ownership.
π Company continues its transition toward an AI-powered logistics/software business while recently refinancing debt with a $2.5M term loan to strengthen its balance sheet.
π When micro-floats like this catch momentum, moves can be explosive. Volume is the key.
Watching closely. ππ
Not financial advice. Do your own DD.
π¨ $VTGN π¨
π Menopause is becoming one of healthcare's biggest untapped markets. Estimates are $15-25B+ by 2030, and many believe that's just the floor.
π Vistagen is developing refisolone (PH80) β a fast-acting investigational nasal spray designed for menopausal hot flashes.
π β
Non-hormonal
π β
Non-systemic
π β
Designed to work through nose-to-brain neurocircuitry in seconds.
π FDA has already issued a "Study May Proceed" letter for the U.S. Phase 2 trial.
π Investors are watching July 21 for potential news surrounding the Fuji Pharma partnership discussions.
π The recent selloff looks overdone to me. If management executes, this could become one of the more interesting women's health stories in biotech.
π Watching closely. Holding.
Not financial advice. For informational purposes only.
$ELAB ππ
πΉοΈ PMGC continues expanding beyond biotech, building positions in aerospace, defense, space, and GLP-1-related technologies through multiple acquisitions and subsidiaries.
πΉοΈ Recent news includes the merger of its aerospace precision manufacturing businesses to streamline operations and improve efficiency while maintaining existing customer relationships.
πΉοΈ The company has also filed new patent applications targeting lean muscle preservation alongside GLP-1 therapies, a rapidly growing area of interest.
πΉοΈ Add in the defense, drone, and space manufacturing exposure, and this story has multiple sectors that continue to attract investor attention.
πΉοΈ If volume continues to build, this is one that could make a strong move. ππ₯
#ELAB #Stocks #SmallCaps #Biotech #Defense
Not financial advice. For informational purposes only.
$SRXH π Loaded target $6+
πΉοΈ Board of Directors has authorized a stock repurchase program to buy back up to 10 million shares, representing up to 50% of shares outstanding.
πΉοΈ Buybacks of this size can significantly reduce the public float while signaling management believes the stock is undervalued.
πΉοΈ Comes on the heels of the company reporting approximately $3.07 per share in preliminary NAV, over $55M in cash and short-term investments, and no debt.
πΉοΈ Definitely one to keep on watch. π
#SRXH #Stocks #SmallCaps #Momentum
Not financial advice. For informational purposes only.
$OSTX ππ
πΉοΈ FDA accepted a new meeting request to review the company's patent-pending OST-HER2 biomarker data, another step toward a potential BLA submission.
πΉοΈ Type B FDA meetings with both CDER and CBER are expected as the company prepares for Accelerated Approval.
πΉοΈ Interim 3-year overall survival data is expected this summer, with a BLA submission targeted for early Fall 2026.
πΉοΈ OST-HER2 already holds Orphan Drug, Fast Track, and Rare Pediatric Disease designations.
πΉοΈ If approved, OSTX expects to receive a Priority Review Voucher (PRV), which management intends to sell. Recent analyst estimates value a PRV around $180M, exceeding the company's current market cap.
πΉοΈ Roth Capital initiated coverage with a Buy rating and a $7 price target, stating approval is "more a question of timing."
π I'm holding this one as a medium-term position. Multiple FDA catalysts ahead.
#OSTX #Biotech #Stocks #SmallCaps
Not financial advice. For informational purposes only.
$VTGN π
πΉοΈ Vistagen received the FDA's "Study May Proceed" letter for refisolone (its non-hormonal treatment for menopausal hot flashes) on April 22.
πΉοΈ Many investors are watching July 21, approximately 90 days later, for a potential update regarding the company's negotiations with Fuji Pharma.
πΉοΈ A definitive licensing agreement, if announced, could potentially include upfront cash, development and sales milestones, and future royalties.
πΉοΈ As of now, no definitive agreement has been announced publicly.
π Worth keeping on the watchlist to see how this develops.
#VTGN #Biotech #Stocks #SmallCaps
Not financial advice. For informational purposes only.
$PFSA π¨π₯
πΉ Recent 1-for-25 reverse split has this setup gaining traction π
πΉ Post-split share count is now tiny β only around 530K shares outstanding β‘
πΉ These reverse split / low-float names can move violently when volume finds them, just like traders saw with $NVVE π
πΉ Not saying it is guaranteed, but the setup is exactly why $PFSA is on watch: tiny supply, momentum building, and traders hunting the next low-float runner π
πΉ Eyes on volume, halts, and whether this becomes the next sympathy move.
#PFSA #NVVE #Stocks #SmallCaps #LowFloat #Momentum Not financial advice. For informational purposes only.
4
1,425
$VTGN ππ§
πΉ I keep adding here. In my opinion, this is way oversold.
πΉ VistaGen still has a late-stage CNS pipeline, with fasedienol targeting social anxiety disorder β a massive unmet need. π
πΉ The market punished the stock hard, but biotech can flip fast when sentiment changes, updates hit, or traders realize the risk/reward has shifted. π
πΉ Not chasing green candles here β Iβm building while fear is high and eyes are off the name. π₯
πΉ Patience required, but I still believe $VTGN has real rebound potential.
#VTGN #Biotech #Stocks #SmallCaps #Momentum Not financial advice. For informational purposes only.
$PFSA π¨ low float watch
πΉ Profusa just completed a 1-for-25 reverse split, effective July 7 π
πΉ Post-split share count dropped from roughly 13.2M shares to only about 530K shares β‘
πΉ That creates an extremely thin trading setup where volume can move this fast in either direction π₯
πΉ Company is a commercial-stage digital health name focused on continuous biochemistry monitoring technology π§¬
πΉ Recent reverse split + tiny post-split float = pure volatility setup. Watching for volume, momentum, and potential continuation π
#PFSA #Stocks #SmallCaps #LowFloat #Momentum Not financial advice. For informational purposes only.
2
1,079
$FRGT ππ
πΉ Still holding. My thesis hasn't changed.
πΉ With an effective tradable float of only around 500K shares, it doesn't take much sustained buying pressure to move this one. π
πΉ I believe this has the potential to make a run toward $10+ over time if momentum returns and the company continues to execute. π
πΉ As always, I'll let the market decideβbut I'm staying patient and holding my position. π
#FRGT #Stocks #SmallCaps #LowFloat #Momentum Not financial advice. For informational purposes only.
1
1
1,091
$VEEE π€π +29% AH
πΉ Twin Vee PowerCats seeing strong after-hours momentum with buyers stepping in π
πΉ The company designs and manufactures recreational and commercial power catamaran boats sold through a growing dealer network π
πΉ No major company news appears to be driving today's move, making price action and volume the key story π
πΉ Tiny market cap + low share count can create explosive moves when momentum traders pile in π₯
πΉ Watching premarket closely. If volume continues to build, traders will be looking for another leg higher tomorrow. π
#VEEE #Stocks #SmallCaps #MomentumNot financial advice. For informational purposes only.
4
1,667
$IOTR π +65% AH
πΉ iOThree just dropped a shareholder letter showing FY2026 revenue growth of 40% to $14.7M π
πΉ Gross profit jumped 68.4% to $3.2M, with gross margin improving from 17.8% to 21.4% π₯
πΉ Company is focused on maritime digital solutions, edge computing, SaaS, satellite connectivity, AI analytics, carbon reporting + shipboard tech βπ€
πΉ CEO says demand across Asia remains healthy, especially Singapore and Taiwan, with Japan expansion targeted for early Q4 2026 π
πΉ Watching this one closely β tiny small-cap maritime tech name, strong AH momentum, real revenue growth, and a digital shipping/AI angle traders may chase π
#IOTR #Stocks #SmallCaps #AI #Maritime #Momentum Not financial advice. For informational purposes only.
1
1,555
$TC π +32% AH
πΉ Token Cat catching strong after-hours momentum π
πΉ No major fresh company PR showing yet β this looks like a pure momentum / low-float type move right now β‘
πΉ Recent trading has been wild with huge volume spikes, big swings, and fast reversals π
πΉ These thin ADR setups can move violently when volume hits β traders watching continuation vs. profit-taking tomorrow π₯
πΉ Eyes on volume, halts, and whether buyers can hold the AH move π
#TC #Stocks #SmallCaps #Momentum Not financial advice. For informational purposes only.
1
1
1,237
$VTAK βοΈπ +59% AH
πΉ Catheter Precision subsidiary Flyte just announced a strategic partnership with LifeVac to equip every Cirrus Vision Jet with LifeVac anti-choking devices π©οΈ
πΉ This adds medical emergency preparedness directly into the cabin β huge focus on passenger safety βοΈ
πΉ Flyte is building around the Cirrus Vision Jet safety stack: CAPS whole-aircraft parachute, Safe Return Emergency Autoland, Garmin safety systems, carbon-fiber airframe + FADEC engine management π₯
πΉ LifeVac is FDA De Novo authorized as a second-line choking rescue device and has been credited with 6,200+ reported rescues worldwide π
πΉ AH momentum is strong here β traders watching volume, float, and whether this safety/aviation angle brings continuation tomorrow π
#VTAK #Stocks #SmallCaps #Aviation #Momentum Not financial advice. For informational purposes only.
3
1,395
$FRGT ππ₯
πΉ Freight Technologies ($FRGT) catching attention with strong AH momentum π
πΉ Extremely low float means it doesn't take much buying pressure to create explosive moves when volume pours in π₯
πΉ AI-powered logistics and cross-border freight platform focused on improving supply chain efficiency π€π¦
πΉ Low-float runners can move fast in both directions β volatility is part of the trade β οΈ
πΉ If momentum continues into tomorrow, this could be one to keep on the watchlist. Eyes on volume and whether buyers can sustain the breakout π
#FRGT #Stocks #LowFloat #Momentum #SmallCaps Not financial advice. For informational purposes only.
2
1,357
